Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 39.17% is in line with its 5-year average of 41.19%, around the middle of its 5-year range (27.10%–50.21%).
As of the fiscal period ended Saturday, June 27, 2026. 11.30% below its 12-month average of 44.16%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-27): 39.17%.
DEBT TO ASSETS RATIO
39.17%
DEBT TO ASSETS RATIO AVG TTM
44.16%
DEBT TO ASSETS RATIO AVG 3Y
47.90%
DEBT TO ASSETS RATIO AVG 5Y
41.19%
DEBT TO ASSETS RATIO AVG 10Y
40.96%
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-11.30%
CURRENT VS 3Y AVG
-18.22%
CURRENT VS 5Y AVG
-4.89%
CURRENT VS 10Y AVG
-4.37%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 536 covered companies
CURRENT VS SECTOR MEDIAN
+39069.91%
vs the sector median at left
Bioventus Inc.
Market Cap
$910.80M
Debt to Assets Ratio
39.17%
TTM Avg
44.16%
3Y Avg
47.90%
5Y Avg
41.19%
Market Cap
$905.71M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$891.36M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$931.24M
Debt to Assets Ratio
0.04%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$857.82M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$855.78M
Debt to Assets Ratio
0.05%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bioventus Inc. (BVS) | $910.80M | 39.17% | 44.16% | 47.90% | 41.19% |
| Arbutus Biopharma Corp (ABUS)vs › | $905.71M | 0.01% | N/A | N/A | N/A |
| HealthStream, Inc. (HSTM)vs › | $918.01M | 0.03% | N/A | N/A | N/A |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $891.36M | 0.00% | N/A | N/A | N/A |
| Kura Oncology, Inc. (KURA)vs › | $931.24M | 0.04% | N/A | N/A | N/A |
| CeriBell, Inc. (CBLL)vs › | $943.26M | 0.13% | N/A | N/A | N/A |
| Jade Biosciences, Inc. (JBIO)vs › | $857.82M | 0.00% | N/A | N/A | N/A |
| Beta Bionics, Inc. (BBNX)vs › | $857.50M | 0.02% | N/A | N/A | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $855.78M | 0.05% | N/A | N/A | N/A |
| Apnimed, Inc. (APMD)vs › | $847.84M | N/A | N/A | N/A | N/A |
Debt/Assets
39.2%
Debt/Equity
1.16
Current Ratio
1.69
Interest Coverage
2.2x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-27 | 39.17% |
| 2026-03-28 | 41.82% |
| 2025-12-31 | 45.55% |
| 2025-09-27 | 45.98% |
| 2025-06-28 | 48.28% |
| 2025-03-29 | 50.03% |
| 2024-12-31 | 46.11% |
| 2024-09-28 | 49.85% |
| 2024-06-29 | 48.38% |
| 2024-03-30 | 49.26% |
| 2023-12-31 | 48.69% |
| 2023-09-30 | 48.65% |
| 2023-07-01 | 46.11% |
| 2023-04-01 | 50.21% |
| 2022-12-31 | 30.46% |
| 2022-10-01 | 30.36% |
| 2022-07-02 | 30.94% |
| 2022-04-02 | 30.77% |
| 2021-12-31 | 29.18% |
| 2021-10-02 | 27.10% |
| 2021-07-03 | 28.00% |
| 2021-04-03 | 28.73% |
| 2020-12-31 | 38.10% |
| 2020-09-30 | 40.33% |
| 2020-06-30 | 51.06% |
| 2019-12-06 | 41.91% |
| 2016-03-31 | 38.22% |
